Gene Variants Indicate Increased Susceptibility to Colon Cancer
|
By LabMedica International staff writers Posted on 08 Mar 2012 |
The imbalance observed in the human tumor tissues appears to be the result of a complex, multistep process by the enzyme sarcoma tyrosine kinase (SRC).
Some tissues, like liver, have just one type of variant of the nuclear receptor hepatocyte nuclear factor 4α (HNF4α), but the colon has both P1 and P2 variants. The P1 variant is found in the nuclei of cells in the normal colon, but in the human colon cancer samples this variant is frequently either absent or located outside of the nucleus and, presumably, no longer functional.
An international team led by cell biologists at the University of California, (Riverside, CA, USA) has uncovered a new insight into colon cancer. The team analyzed about 450 human colon cancer specimens and found that in nearly 80% of them, the variants of the HNF4A gene are out of balance. The team used both SRC kinase assays and human colonic adenocarcinoma tissue staining. Tissue microarrays (TMAs) were constructed with 1.0 mm cores from morphologically representative areas of the original archived paraffin blocks, the central region of the tumor, deep advancing tumor front, and adjacent non-neoplastic mucosa using an Advanced Tissue Arrayer, ATA-100.
SRC kinase has been known to be activated in colon cancer but, until now, it was not known to act on the HNF4α protein. The cell biologists found that activated SRC modifies the P1 but not the P2 variant. The net result is loss of the P1 variant in the nuclei of cells in the colon. Another factor that increased a person's susceptibility to the disease was specific single nucleotide polymorphisms or SNPs located in the HNF4A gene. An SNP is a DNA sequence variation, a minor change in the genomic sequence that accounts for the variations seen between individuals. SNPs are the most common type of genetic variation among people. The SRC kinase assays and the ATA-100 used are manufactured by Millipore (Billerica, MA, USA).
The authors concluded that that increased staining for active SRC is associated with a loss of nuclear P1-HNF4α in a sizeable cohort of human colorectal tumors. Their findings suggest a unique link between an oncogenic kinase, a potent differentiation factor, and human colon cancer. Frances M. Sladek, PhD, a professor of cell biology and toxicologist, who was the lead author of the study said, "Loss of nuclear P1 HNF4α protein in the colon may be an early sign of colon cancer. A healthy colon has a good but delicate balance of the two HNF4A variants. If you could prevent the loss of the P1 variant via drugs, you might be able to maintain a normal colon and prevent colon cancer." The study was published on Febraury 14, 2012, in the Proceedings of the National Academy of Science of the United States (PNAS).
Related Links:
University of California, Riverside
Millipore
Some tissues, like liver, have just one type of variant of the nuclear receptor hepatocyte nuclear factor 4α (HNF4α), but the colon has both P1 and P2 variants. The P1 variant is found in the nuclei of cells in the normal colon, but in the human colon cancer samples this variant is frequently either absent or located outside of the nucleus and, presumably, no longer functional.
An international team led by cell biologists at the University of California, (Riverside, CA, USA) has uncovered a new insight into colon cancer. The team analyzed about 450 human colon cancer specimens and found that in nearly 80% of them, the variants of the HNF4A gene are out of balance. The team used both SRC kinase assays and human colonic adenocarcinoma tissue staining. Tissue microarrays (TMAs) were constructed with 1.0 mm cores from morphologically representative areas of the original archived paraffin blocks, the central region of the tumor, deep advancing tumor front, and adjacent non-neoplastic mucosa using an Advanced Tissue Arrayer, ATA-100.
SRC kinase has been known to be activated in colon cancer but, until now, it was not known to act on the HNF4α protein. The cell biologists found that activated SRC modifies the P1 but not the P2 variant. The net result is loss of the P1 variant in the nuclei of cells in the colon. Another factor that increased a person's susceptibility to the disease was specific single nucleotide polymorphisms or SNPs located in the HNF4A gene. An SNP is a DNA sequence variation, a minor change in the genomic sequence that accounts for the variations seen between individuals. SNPs are the most common type of genetic variation among people. The SRC kinase assays and the ATA-100 used are manufactured by Millipore (Billerica, MA, USA).
The authors concluded that that increased staining for active SRC is associated with a loss of nuclear P1-HNF4α in a sizeable cohort of human colorectal tumors. Their findings suggest a unique link between an oncogenic kinase, a potent differentiation factor, and human colon cancer. Frances M. Sladek, PhD, a professor of cell biology and toxicologist, who was the lead author of the study said, "Loss of nuclear P1 HNF4α protein in the colon may be an early sign of colon cancer. A healthy colon has a good but delicate balance of the two HNF4A variants. If you could prevent the loss of the P1 variant via drugs, you might be able to maintain a normal colon and prevent colon cancer." The study was published on Febraury 14, 2012, in the Proceedings of the National Academy of Science of the United States (PNAS).
Related Links:
University of California, Riverside
Millipore
Latest Molecular Diagnostics News
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








